Detail akcie Aquestive Therp Rg online

Business Summary: Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aquestive Therapeutics Inc revenues decreased 31% to $31.5M. Net loss increased 92% to $51.9M. Revenues reflect United States segment decrease of 34% to $20.2M, Ex-United States segment decrease of 25% to $11.3M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase from $8.3M to $42.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.33 to -$0.52.